Home › Education › How Physicians Recommend Peptides
Education · Tier 1How Do Physicians Recommend Peptides to Patients?
The honest map of how doctors actually decide whether to recommend a peptide, what evidence they weigh, and what specialty coordination matters.
Physicians follow evidence-graded frameworks when deciding to recommend peptide therapy.
FDA-approved peptides like Wegovy, Ozempic, and Forteo have established prescribing standards.
Off-label or compounded peptides require additional risk-benefit assessment and documented informed consent.
This page is educational and does not constitute medical advice. The information presented reflects published research, FDA prescribing information, AMA Code of Medical Ethics, FDA Compounding Quality Act framework, and society guidelines as referenced.
Quick Answer
Physicians follow a structured framework when deciding to recommend peptides. The framework begins with comprehensive evaluation including history, exam, and indicated labs.
For FDA-approved indications, prescribing follows established standards in the FDA prescribing information. Semaglutide as Wegovy or Ozempic is FDA-approved for chronic weight management and type 2 diabetes with cardiovascular benefit. Tirzepatide as Zepbound or Mounjaro is FDA-approved for chronic weight management and type 2 diabetes. Teriparatide as Forteo is FDA-approved for postmenopausal, male, and glucocorticoid-induced osteoporosis at high fracture risk. Romosozumab as Evenity is FDA-approved for postmenopausal osteoporosis at high fracture risk.
For off-label use of FDA-approved peptides, AMA Code of Medical Ethics requires risk-benefit justification, informed consent, and documentation. For compounded peptides, the physician evaluates the 503A or 503B pharmacy quality assurance, third-party testing, and sourcing.
Research-grade peptides without FDA approval are generally not recommended outside formal research framework. Specialty coordination across primary care, endocrinology, weight medicine, rheumatology, and other fields ensures appropriate matching to validated standard-of-care.
For specific scenarios, see Peptides for Type 2 Diabetes, Peptides for Bone Health, and Peptides for Cardiovascular Health.
Peptide therapy spans a wide regulatory and evidence spectrum. FDA-approved peptides include Semaglutide as Wegovy and Ozempic. Tirzepatide is FDA-approved as Zepbound and Mounjaro. Liraglutide is FDA-approved as Saxenda and Victoza. Teriparatide is FDA-approved as Forteo. Abaloparatide is FDA-approved as Tymlos. Romosozumab is FDA-approved as Evenity. Sermorelin and Tesamorelin as Egrifta are also FDA-approved. These have Phase 3 trial evidence and established prescribing information. Off-label use of FDA-approved peptides is legal but requires informed consent per AMA Code of Medical Ethics. Compounded peptides come from 503A or 503B pharmacies under state pharmacy board oversight. Research-grade peptides without FDA approval are not within validated clinical practice. Specialty coordination across primary care, endocrinology, weight medicine, and relevant fields is the standard framework. PSI tracks all these distinctions evidence-graded.
WHICH PATIENT CONTEXT?
At a Glance: How Physicians Recommend Peptides
| Patient Context | Subtitle | Animal Evidence | Human Evidence | Physician Approach |
|---|---|---|---|---|
| Adult with FDA-approved-indication condition | FDA-approved prescribing | — | Strong | Wegovy / Ozempic / Forteo / Evenity per labeling and guidelines |
| Adult exploring off-label use of FDA-approved peptide | Risk-benefit + informed consent | — | Moderate | AMA Code of Ethics framework; document rationale |
| Adult exploring compounded peptide | Compounding pharmacy due diligence | — | Moderate | 503A or 503B accredited + third-party testing |
| Adult exploring research-grade peptide | Generally outside validated practice | — | Limited | Refer to clinical trial enrollment when appropriate |
| Patient with multiple comorbidities | Comprehensive evaluation + specialty coordination | — | Strong | Multi-specialty review and coordinated care plan |
| Patient with specific contraindications | Risk assessment + alternative therapy | — | Strong | Defer to validated alternatives within FDA-approved scope |
| Patient with limited evidence for their condition | Defer to validated standard-of-care | — | Moderate | Validated guideline-directed therapy first |
| Patient on existing complex regimen | Drug interaction review + coordination | — | Strong | Comprehensive medication reconciliation and monitoring plan |
How Physicians Actually Decide
This page covers how physicians approach the decision to recommend peptide therapy. The framework spans five stages. Stage one is comprehensive evaluation. Stage two is treatment option consideration matched to FDA-approved indications. Stage three is risk-benefit assessment for off-label or compounded options. Stage four is informed consent and documentation per AMA Code of Medical Ethics. Stage five is monitoring plan establishment with appropriate follow-up cadence.
Comprehensive Evaluation Comes First
Every peptide recommendation begins with structured evaluation matching workup intensity to clinical complexity.
Comprehensive evaluation includes detailed history covering current symptoms, prior therapy responses, comorbidities, medications, allergies, family history, and lifestyle factors. Physical exam focuses on systems relevant to the indication. Baseline labs depend on the intended therapy class and include glycemic markers (HbA1c, fasting glucose) for GLP-1 RA prescribing, bone density and biochemical markers for anabolic osteoporosis peptide prescribing, hormone panels for HRT or sexual health peptide prescribing, and comprehensive metabolic panels universally. Specialty coordination across primary care, endocrinology, rheumatology, weight medicine, or other relevant fields is the standard framework per AMA Code of Medical Ethics.
FDA-Approved Pathways Use Established Standards
When an FDA-approved peptide matches the indication, prescribing follows the FDA prescribing information.
FDA-approved peptides have detailed prescribing information including indication, contraindications, warnings, dosing, monitoring requirements, and adverse event profiles. Wegovy and Ozempic carry FDA approval for chronic weight management and type 2 diabetes with cardiovascular benefit. Zepbound and Mounjaro carry FDA approval for chronic weight management and type 2 diabetes. Saxenda and Victoza carry FDA approval for chronic weight management and type 2 diabetes. Forteo carries FDA approval for postmenopausal, male, and glucocorticoid-induced osteoporosis. Tymlos carries FDA approval for postmenopausal and male osteoporosis. Evenity carries FDA approval for postmenopausal osteoporosis at high fracture risk. Sermorelin carries FDA approval history for growth hormone deficiency. Tesamorelin as Egrifta carries FDA approval for HIV-associated lipodystrophy. Physicians match patient presentation to FDA-approved indications and follow the prescribing information.
Off-Label Use Requires Risk-Benefit Justification
Off-label use of FDA-approved peptides is legal but requires documented informed consent and risk-benefit assessment per AMA Code of Medical Ethics.
Off-label prescribing is legal when supported by evidence, sound medical judgment, and informed consent. The AMA Code of Medical Ethics requires the physician to weigh evidence base, alternative treatments, patient-specific factors, and document the rationale. Examples include Ozempic for weight management before Wegovy was available, BPC-157 considerations outside FDA-approved scope, and various other contexts. Informed consent documentation covers the off-label status, evidence base, alternatives, risks, expected benefits, and monitoring plan. Specialty coordination strengthens off-label decisions through documented multi-specialty review.
Compounded Peptides Require Pharmacy Due Diligence
Compounded peptides come from 503A or 503B pharmacies under state pharmacy board oversight; physician due diligence on quality assurance is essential.
503A pharmacies compound for individual patient prescriptions under state pharmacy board oversight. 503B outsourcing facilities compound in bulk under FDA oversight. Neither category receives FDA pre-market approval for the compounded product. Physician due diligence includes verifying pharmacy accreditation, third-party purity and potency testing, sterility certification, USP standards compliance, and adverse event reporting practices. Recent FDA scrutiny on compounded GLP-1 receptor agonists has highlighted the importance of careful sourcing. Informed consent documentation for compounded products covers the regulatory status, quality assurance basis, and risk-benefit framing distinct from FDA-approved alternatives.
Specialty Coordination Strengthens Decisions
Multi-specialty coordination across primary care, endocrinology, weight medicine, rheumatology, and relevant fields ensures appropriate matching to validated standard-of-care.
Primary care typically manages routine evaluation, screening, and FDA-approved peptide prescribing for common indications. Endocrinology manages complex hormone or metabolic peptide therapy. Weight medicine specialists manage obesity-focused GLP-1 RA prescribing. Rheumatology manages osteoporosis with rheumatologic conditions or glucocorticoid-induced disease. Geriatrics manages osteoporosis in older adults with fall risk. Cardiology manages cardiovascular indications. Urology manages male sexual health peptide considerations. Functional medicine and anti-aging medicine specialists frequently work with both FDA-approved and compounded peptides. Specialty coordination provides depth of expertise for complex cases.
FDA-approved vs off-label vs compounded vs research-grade peptides
The four-tier regulatory spectrum and how physicians navigate it
FDA-approved peptides have the strongest regulatory and evidence foundation. The FDA approval process requires Phase 3 trial evidence demonstrating safety and efficacy for specific indications. FDA-approved peptides include Semaglutide as Wegovy for chronic weight management and CV risk reduction, Ozempic for type 2 diabetes with cardiovascular benefit, and Rybelsus for type 2 diabetes. Tirzepatide is FDA-approved as Zepbound for chronic weight management and Mounjaro for type 2 diabetes. Liraglutide is FDA-approved as Saxenda for chronic weight management and Victoza for type 2 diabetes. Teriparatide is FDA-approved as Forteo for postmenopausal, male, and glucocorticoid-induced osteoporosis at high fracture risk. Abaloparatide is FDA-approved as Tymlos for postmenopausal and male osteoporosis at high fracture risk. Romosozumab is FDA-approved as Evenity for postmenopausal osteoporosis at high fracture risk. Sermorelin and Tesamorelin as Egrifta also carry FDA approval. Physicians prescribing within FDA-approved indications follow the FDA prescribing information.
Off-label use of FDA-approved peptides is legal under AMA Code of Medical Ethics when supported by evidence, sound medical judgment, and informed consent. Off-label use commonly arises when an FDA-approved peptide has evidence for a related indication not yet in the FDA labeling. Physicians document the off-label status, evidence base, alternatives considered, risk-benefit assessment, and patient consent. Specialty coordination strengthens off-label decisions through documented multi-specialty review.
Compounded peptides come from 503A pharmacies (individual patient prescriptions) or 503B outsourcing facilities (bulk compounding under FDA oversight). Neither category receives FDA pre-market approval for the compounded product. Physician due diligence includes verifying pharmacy accreditation, third-party purity and potency testing, sterility certification, USP standards compliance, and adverse event reporting practices. Recent FDA scrutiny on compounded GLP-1 receptor agonists highlights the importance of careful sourcing. Informed consent for compounded products covers regulatory status, quality assurance basis, and risk-benefit framing distinct from FDA-approved alternatives.
Research-grade peptides without FDA approval are generally outside validated clinical practice. Examples include BPC-157, MOTS-c, GHK-Cu in injectable form, and various other compounds with animal-only or early human evidence. Physicians do not typically recommend these outside formal clinical trial enrollment. The evidence base, quality control, and regulatory oversight are absent. Patients pursuing these compounds typically do so outside FDA-approved frameworks at their own risk. PSI tracks all evidence levels evidence-graded.
Specialty matching for peptide therapy decisions
Primary care vs endocrinology vs weight medicine vs rheumatology vs other specialties
Primary care typically manages routine screening, evaluation, and FDA-approved peptide prescribing for common indications. Primary care physicians prescribe Wegovy and Ozempic for weight management and type 2 diabetes when patients meet FDA-approved criteria. Primary care manages comprehensive evaluation, monitoring, and care coordination. Complex cases or off-label considerations typically trigger specialty referral.
Endocrinology specialty manages complex hormone or metabolic peptide therapy. Endocrinologists frequently prescribe FDA-approved GLP-1 receptor agonists, growth hormone secretagogues, and anabolic osteoporosis peptides. Endocrinology coordinates secondary cause workup for osteoporosis, manages complex diabetes regimens, and oversees hormone replacement therapy. Endocrinology coordination is appropriate for patients with multiple metabolic comorbidities or complex pituitary axis disorders.
Weight medicine specialty (obesity medicine) manages comprehensive obesity care with focus on chronic weight management. Obesity medicine specialists frequently prescribe FDA-approved Wegovy, Zepbound, and Saxenda within established frameworks. The American Board of Obesity Medicine certifies specialists with focused obesity expertise. Comprehensive obesity care includes lifestyle, behavioral, pharmacological, and surgical considerations.
Rheumatology specialty manages osteoporosis with rheumatologic conditions or glucocorticoid-induced disease. Geriatrics specialty manages osteoporosis in older adults with fall risk. Cardiology manages cardiovascular indications including SELECT-supported Wegovy use. Urology manages male sexual health peptide considerations. Functional medicine and anti-aging medicine specialists frequently work with both FDA-approved and compounded peptides under specialty frameworks.
Informed consent and documentation per AMA Code of Medical Ethics
The legal and ethical framework for prescribing decisions
AMA Code of Medical Ethics establishes the framework for prescribing decisions. Informed consent requires disclosure of indication, evidence base, alternatives, expected benefits, risks including common and serious adverse events, monitoring requirements, and the off-label or compounded status when applicable. The physician documents the consent process in the medical record. Off-label prescribing decisions carry additional documentation requirements per the AMA Code.
Documentation standards include the indication, evidence base justification, alternative treatments considered, patient-specific factors weighing into the decision, monitoring plan, and follow-up cadence. For off-label use, documentation specifies the off-label status and rationale. For compounded products, documentation specifies the pharmacy source, quality assurance basis, and informed consent for the compounded nature.
Patient education is part of informed consent. The physician explains the therapy in language appropriate to patient understanding, addresses questions, and confirms comprehension. Written patient information may supplement verbal discussion. Educational resources from PSI and other evidence-graded sources support patient education. Patient education includes monitoring expectations, side effect recognition, and when to contact the physician.
The compounding pharmacy decision framework
503A vs 503B vs research suppliers and physician due diligence
503A pharmacies compound for individual patient prescriptions under state pharmacy board oversight. The pharmacy receives the prescription from a licensed physician and compounds the product for the specific patient. State pharmacy boards regulate 503A operations. The FDA does not pre-approve 503A compounded products. Physician due diligence includes verifying state license, accreditation status, and third-party testing practices.
503B outsourcing facilities compound in bulk under FDA oversight. The FDA registers and inspects 503B facilities. 503B compounded products may be used by physicians for office stock or specific patient prescriptions. Physician due diligence for 503B includes verifying FDA registration, inspection history, and adverse event reporting.
Research suppliers selling 'research-grade' or 'not for human use' peptides operate outside FDA and state pharmacy board oversight. These suppliers are not appropriate sourcing for therapeutic peptide use. Physicians do not recommend research supplier products for clinical use. Patients self-sourcing from research suppliers are outside validated clinical practice and incur unknown quality, purity, and safety risks.
Research Suggests
Direction
Physicians follow evidence-graded frameworks calibrated to the regulatory status and evidence base of each peptide.
The decision framework spans five stages. Stage one is comprehensive evaluation including history, exam, and indicated labs. Stage two matches patient presentation to FDA-approved indications when available. Stage three assesses risk-benefit for off-label or compounded considerations per AMA Code of Medical Ethics. Stage four establishes informed consent with documentation. Stage five establishes monitoring plan and follow-up cadence. The framework calibrates intensity to clinical complexity. Simple FDA-approved indication prescribing in primary care follows established standards. Complex multi-system or off-label considerations trigger specialty referral and multi-specialty coordination.
Strongest evidence
FDA-approved peptide prescribing has the strongest evidence and regulatory foundation across all therapeutic peptide use.
FDA-approved peptides have Phase 3 trial evidence demonstrating safety and efficacy for specific indications. Wegovy SELECT demonstrated 20 percent MACE reduction. Ozempic SUSTAIN-6 demonstrated cardiovascular benefit in T2DM. Zepbound SURMOUNT demonstrated approximately 21 percent weight reduction. Forteo Phase 3 demonstrated approximately 65 percent vertebral fracture reduction. Tymlos ACTIVE Phase 3 demonstrated approximately 86 percent vertebral fracture reduction. Evenity FRAME demonstrated 73 percent vertebral fracture reduction. These FDA approvals come with prescribing information including indication, contraindications, dosing, monitoring, and adverse event profiles that guide prescribing decisions. Physicians prescribing FDA-approved peptides within indications have the strongest evidence support and clearest framework.
Limitations
Off-label and compounded peptides have less regulatory oversight and require additional risk-benefit assessment.
Off-label use of FDA-approved peptides is legal but requires documented informed consent and risk-benefit justification. The evidence base for off-label indications varies. Compounded peptides do not receive FDA pre-market approval for the compounded product. Quality assurance depends on pharmacy practices including third-party testing. Research-grade peptides without FDA approval are outside validated clinical practice. The evidence base, quality control, and regulatory oversight are absent. Patient self-sourcing from research suppliers incurs unknown safety risks. PSI does not recommend research-grade peptide use outside formal clinical trial enrollment.
Assessment
Validated FDA-approved framework dominates evidence-graded peptide practice. Off-label and compounded options apply selectively under specialty coordination.
PSI's reading: validated FDA-approved peptide prescribing per FDA prescribing information dominates evidence-graded practice. The decision framework calibrates intensity to clinical complexity. Simple FDA-approved indication prescribing in primary care follows established standards with appropriate monitoring. Complex cases warrant specialty coordination across endocrinology, weight medicine, rheumatology, and relevant fields. Off-label use of FDA-approved peptides applies selectively under AMA Code of Medical Ethics framework with documented informed consent. Compounded peptide use requires physician due diligence on pharmacy quality assurance. Research-grade peptide use is generally outside validated practice. Anyone framing research-grade peptides as substitute for validated FDA-approved therapy is reading further than the evidence supports.
How to Approach Your Decision
- For FDA-approved indication, work with primary care or appropriate specialty within FDA prescribing information framework.
- For chronic weight management, primary care, weight medicine, or endocrinology prescribe FDA-approved Wegovy, Zepbound, or Saxenda.
- For type 2 diabetes with CV benefit, endocrinology or primary care prescribe FDA-approved Ozempic, Mounjaro, or Victoza.
- For high fracture risk osteoporosis, endocrinology or rheumatology prescribe FDA-approved Forteo, Tymlos, or Evenity.
- For off-label use of FDA-approved peptide, document risk-benefit assessment and informed consent per AMA Code of Medical Ethics.
- For compounded peptide consideration, verify pharmacy accreditation, third-party testing, and 503A or 503B status.
- For research-grade peptide consideration, refer to clinical trial enrollment rather than self-sourcing.
- For complex multi-system patients, multi-specialty coordination across primary care, endocrinology, and relevant fields strengthens decisions.
Limitations and Caveats
- FDA-approved indications carry the strongest evidence base. Phase 3 trial evidence with FDA prescribing information establishes prescribing standards.
- Off-label use is legal but requires informed consent. AMA Code of Medical Ethics governs the framework with documentation requirements.
- Compounded peptides do not receive FDA pre-market approval. Quality assurance depends on pharmacy practices and third-party testing.
- Research-grade peptides are outside validated clinical practice. Animal-only or early human evidence does not support clinical recommendation.
- Patient self-sourcing from research suppliers incurs unknown safety risks. Quality, purity, and sterility are not guaranteed outside FDA framework.
- Specialty coordination strengthens complex decisions. Multi-system patients benefit from documented multi-specialty review per AMA Code.
- Insurance coverage varies by indication and product. FDA-approved indications generally have better coverage than off-label or compounded use.
- Monitoring requirements differ by peptide class. Comprehensive monitoring plans calibrate intensity to therapy class and patient factors.
Common Misconceptions
Claim: All peptides require a prescription from a specialist.
Reality: Primary care physicians can and do prescribe FDA-approved peptides for common indications including chronic weight management with Wegovy and type 2 diabetes with Ozempic. Complex multi-system patients or off-label considerations typically trigger specialty referral. Endocrinology, weight medicine, rheumatology, and other specialties manage more complex cases.
Claim: Compounded peptides are equivalent to FDA-approved versions.
Reality: Compounded peptides do not undergo FDA pre-market approval. Quality, purity, and sterility depend on the compounding pharmacy practices including third-party testing and USP standards compliance. FDA-approved Wegovy and Ozempic have Phase 3 trial evidence and rigorous quality control that compounded versions do not match by default.
Claim: Off-label peptide use is illegal.
Reality: Off-label use of FDA-approved peptides is legal under AMA Code of Medical Ethics when supported by evidence, sound medical judgment, and documented informed consent. The physician documents the off-label status, evidence base, alternatives considered, and risk-benefit assessment in the medical record. Specialty coordination strengthens off-label decisions.
Claim: Research-grade peptides from online suppliers are safe with proper dosing.
Reality: Research suppliers selling research-grade or not-for-human-use peptides operate outside FDA and state pharmacy board oversight. Quality, purity, sterility, and adverse event reporting are not guaranteed. Patient self-sourcing from research suppliers incurs unknown safety risks. PSI does not recommend research-grade peptide use outside formal clinical trial enrollment.
Claim: My doctor will prescribe any peptide I request.
Reality: Physicians weigh evidence base, FDA approval status, indications, contraindications, patient-specific factors, and risk-benefit assessment when making prescribing decisions. Not all patient requests align with medical judgment. Patients may discuss requests openly with their physician, but the prescribing decision reflects clinical judgment and the AMA Code of Medical Ethics.
Claim: Compounded GLP-1 peptides are the same as Wegovy or Ozempic.
Reality: Compounded GLP-1 receptor agonist products lack FDA pre-market approval and have faced increasing FDA scrutiny. The FDA has issued specific guidance on compounded semaglutide and tirzepatide products. Quality varies by pharmacy. Compounded products do not match the rigorous Phase 3 trial evidence and quality control of Wegovy and Ozempic by default. Patients pursuing compounded GLP-1s should work with physicians who verify pharmacy quality assurance.
Claim: Insurance always covers FDA-approved peptide prescriptions.
Reality: Coverage varies by indication, prior authorization requirements, formulary tier, and specific product. Chronic weight management indications often require documented BMI thresholds, comorbidity documentation, and prior lifestyle intervention attempts. Type 2 diabetes indications generally have better coverage. Off-label and compounded prescriptions often have limited or no coverage. Patients should discuss coverage with their physician and insurance.
Frequently Asked Questions
Do all peptides require a prescription?
In the United States, all therapeutic peptides require a prescription from a licensed physician. FDA-approved peptides like Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Forteo, Tymlos, and Evenity are prescription medications. Compounded peptides require a prescription routed through a 503A or 503B compounding pharmacy. Research suppliers selling peptides without a prescription are operating outside FDA and state pharmacy board frameworks.
Can my primary care doctor prescribe peptides?
Yes, primary care physicians frequently prescribe FDA-approved peptides for common indications. Common primary care peptide prescribing includes Wegovy and Saxenda for chronic weight management, Ozempic and Victoza for type 2 diabetes, and growth hormone secretagogues. Complex multi-system patients, off-label considerations, or specific specialty disorders typically trigger referral to endocrinology, weight medicine, rheumatology, or other relevant specialists.
What's the difference between FDA-approved and compounded peptides?
FDA-approved peptides have undergone Phase 3 clinical trials demonstrating safety and efficacy for specific indications. The FDA reviews safety, efficacy, manufacturing quality, and labeling before approval. Compounded peptides come from 503A pharmacies (individual patient prescriptions) or 503B outsourcing facilities (bulk compounding). Neither category receives FDA pre-market approval for the compounded product. See [Compounded vs FDA-approved peptides](/education/compounded-vs-fda-approved-peptides) for detailed comparison.
Is off-label peptide use legal?
Yes, off-label use of FDA-approved peptides is legal in the United States when supported by evidence, sound medical judgment, and documented informed consent per AMA Code of Medical Ethics. The physician documents the off-label status, evidence base, alternatives considered, risk-benefit assessment, and patient consent in the medical record. Specialty coordination strengthens off-label decisions through documented multi-specialty review.
What is AMA Code of Medical Ethics for off-label prescribing?
AMA Code of Medical Ethics Opinion 1.1.5 addresses off-label prescribing. The physician may prescribe a drug off-label when supported by evidence, sound medical judgment, and informed consent. The physician must weigh the evidence base, alternative treatments, patient-specific factors, and document the rationale. Informed consent covers the off-label status, evidence base, alternatives, risks, expected benefits, and monitoring plan.
What is a 503A vs 503B compounding pharmacy?
503A pharmacies compound for individual patient prescriptions under state pharmacy board oversight. The pharmacy receives the prescription from a licensed physician for a specific patient. State pharmacy boards regulate 503A operations. 503B outsourcing facilities compound in bulk under FDA oversight. The FDA registers and inspects 503B facilities. 503B compounded products may be used by physicians for office stock or specific patient prescriptions. Neither category receives FDA pre-market approval for the compounded product.
What is the AMA Code requirement for informed consent?
AMA Code of Medical Ethics requires the physician to disclose the indication, evidence base, alternatives, expected benefits, risks (including common and serious adverse events), monitoring requirements, and the off-label or compounded status when applicable. The physician documents the consent process in the medical record. Patient education is part of informed consent. The physician explains the therapy in language appropriate to patient understanding, addresses questions, and confirms comprehension.
Should I see a specialist for peptide therapy?
It depends on the indication and complexity. Primary care typically manages routine FDA-approved peptide prescribing for common indications like chronic weight management or type 2 diabetes. Endocrinology manages complex hormone or metabolic peptide therapy. Weight medicine specialists manage comprehensive obesity care. Rheumatology manages osteoporosis with rheumatologic conditions. Multi-specialty coordination is appropriate for complex multi-system patients. See [Finding a peptide doctor](/education/finding-a-peptide-doctor) for specialty matching guidance.
What baseline evaluation will my physician do?
Comprehensive baseline evaluation includes detailed history, focused physical exam, and indicated laboratory testing. Specific labs depend on the therapy class and indication. For GLP-1 receptor agonist prescribing, baseline labs typically include HbA1c, fasting glucose, lipid panel, comprehensive metabolic panel, TSH, and pregnancy test where applicable. For anabolic osteoporosis peptide prescribing, baseline labs include DEXA T-score, FRAX, calcium, vitamin D, PTH, and secondary cause workup. See [Bloodwork before peptide therapy](/education/bloodwork-before-peptide-therapy) for class-specific panels.
How does FDA approval affect peptide prescribing?
FDA approval provides the strongest evidence and regulatory foundation for peptide prescribing. FDA-approved peptides have Phase 3 trial evidence demonstrating safety and efficacy for specific indications. The FDA prescribing information includes indication, contraindications, warnings, dosing, monitoring requirements, and adverse event profiles. Physicians prescribing FDA-approved peptides within indications have established standards to follow. Off-label use of FDA-approved peptides requires additional documentation and informed consent per AMA Code.
What if there's no FDA-approved peptide for my condition?
When no FDA-approved peptide matches the indication, the physician evaluates validated standard-of-care alternatives first. For conditions where peptide therapy has emerging evidence but no FDA approval, options include off-label use of FDA-approved peptides with related indications, clinical trial enrollment, or deferral to validated alternatives. Research-grade peptides without FDA approval are generally outside validated clinical practice. Specialty coordination ensures appropriate matching to evidence-graded options.
Can I get a peptide prescription via telehealth?
Yes, telehealth prescribing of peptides is legal in the United States when the physician-patient relationship is established and state regulations are followed. Telehealth peptide prescribing is most common for FDA-approved indications like chronic weight management with Wegovy. The physician conducts a comprehensive evaluation including history, indicated labs, and follow-up. See [Telehealth vs in-person peptide prescriptions](/education/telehealth-vs-in-person-peptide-prescriptions) for setting comparison.
How long does the peptide consultation process take?
The initial consultation typically takes 45 to 75 minutes for comprehensive evaluation including history, exam, and indicated labs ordering. The decision-making and prescribing visit may follow after labs return, typically 1 to 2 weeks later. Follow-up visits are typically 15 to 30 minutes at 4 to 12 week intervals depending on therapy class. See [Peptide consultation what to expect](/education/peptide-consultation-what-to-expect) for the visit experience.
What if my insurance doesn't cover the peptide?
Coverage varies by indication, prior authorization requirements, formulary tier, and specific product. For FDA-approved peptides like Wegovy and Ozempic, prior authorization is common and requires documented BMI thresholds, comorbidity documentation, and prior intervention attempts. Manufacturer savings programs (NovoCare for Wegovy and Ozempic, LillyDirect for Zepbound and Mounjaro) may reduce out-of-pocket costs. Compounded products are typically not covered by insurance. Discuss coverage with your physician and insurance.
What's the difference between primary care and specialty peptide prescribing?
Primary care typically manages routine FDA-approved peptide prescribing for common indications, comprehensive evaluation, and ongoing monitoring. Primary care prescribes Wegovy, Ozempic, Saxenda, and similar FDA-approved products within established frameworks. Specialty practice manages complex multi-system patients, off-label considerations, complex hormone disorders, severe osteoporosis with anabolic therapy, and rheumatologic or geriatric considerations. Multi-specialty coordination across primary care and specialty is common for complex patients.
What questions should I ask my doctor about peptide therapy?
Ask: (1) Is the peptide FDA-approved for my indication, or is the use off-label or compounded? (2) What evidence supports the recommendation? (3) What alternative treatments are available? (4) What baseline labs and monitoring will be required? (5) What are the common and serious side effects? (6) What is the expected timeline and how is response measured? (7) What is the insurance coverage and out-of-pocket cost? (8) For compounded products, what pharmacy and what quality assurance? See [Questions to ask your peptide doctor](/education/questions-to-ask-your-peptide-doctor).
Sourcing Checklist
Verify FDA-approved status for the indication.
If FDA-approved for the patient indication, prescribe per FDA prescribing information including indication, contraindications, dosing, and monitoring requirements.
For off-label use, document evidence base and risk-benefit assessment.
Off-label use of FDA-approved peptides is legal per AMA Code of Medical Ethics with documented evidence base, alternatives considered, risk-benefit assessment, and informed consent.
For compounded products, verify pharmacy accreditation and quality assurance.
503A or 503B pharmacy with state pharmacy board oversight (503A) or FDA registration (503B). Third-party testing, USP standards compliance, and adverse event reporting practices.
Document informed consent with regulatory status disclosed.
Informed consent covers indication, evidence base, alternatives, risks, benefits, monitoring plan, and the FDA-approved or off-label or compounded status per AMA Code of Medical Ethics.
Establish baseline labs and monitoring plan calibrated to therapy class.
Baseline labs match the FDA prescribing information requirements for FDA-approved peptides, or class-appropriate biomarkers for off-label use. Monitoring cadence calibrates to therapy class and patient factors.
Coordinate with relevant specialty when clinical complexity warrants.
Endocrinology, weight medicine, rheumatology, cardiology, urology, and other specialties manage complex multi-system patients, off-label considerations, and specific disorder presentations.
Regulatory Context
The regulatory landscape for peptide prescribing evolves continuously. The FDA has issued increasing scrutiny on compounded GLP-1 receptor agonist products with specific guidance on compounded semaglutide and tirzepatide. AMA Code of Medical Ethics continues to refine off-label prescribing standards including documentation requirements. FDA-approved peptide indications continue to expand with new Phase 3 trial readouts including Wegovy SELECT for CV risk reduction in obesity without diabetes (2023), Romosozumab Evenity approval for postmenopausal osteoporosis at high fracture risk (2019), and Abaloparatide Tymlos approval expansion for male osteoporosis (2022). Tirzepatide SURPASS-CVOT and Retatrutide TRIUMPH-1 cardiovascular outcomes trials are ongoing. PSI tracks these developments and updates this page as material changes occur.
Comparison
| Category | FDA-approved | Off-label (FDA-approved peptide) | Compounded | Research-grade |
|---|---|---|---|---|
| Regulatory oversight | FDA pre-market approval | FDA-approved drug, off-label use | 503A state board / 503B FDA registration | Outside FDA framework |
| Evidence base | Phase 3 trial evidence | Variable, off-label evidence | No pre-market trial evidence for compounded form | Animal-only or early human |
| Quality assurance | FDA manufacturer standards | FDA manufacturer standards | Pharmacy practices + third-party testing | Not assured |
| Informed consent | Standard medical informed consent | Documented off-label per AMA Code | Documented compounded status + quality basis | Generally not appropriate for clinical use |
| Insurance coverage | Generally covered with prior auth | Often not covered or limited | Typically not covered | Not applicable |
| Specialty involvement | Primary care or specialty per indication | Specialty coordination strengthens | Specialty due diligence appropriate | Outside validated practice |
| PSI recommendation | Primary recommended path within indications | Acceptable with documented framework | Acceptable with verified pharmacy quality | Generally not recommended outside trials |
Who This Applies To
- • Adult with FDA-approved indication condition (type 2 diabetes, chronic weight management, osteoporosis) considering direct FDA-approved peptide prescribing per FDA prescribing information.
- • Adult with chronic weight management need considering FDA-approved Wegovy, Zepbound, or Saxenda with primary care or weight medicine specialty.
- • Adult with type 2 diabetes and cardiovascular risk considering FDA-approved Ozempic, Mounjaro, or Victoza with endocrinology or primary care.
- • Adult with high fracture risk osteoporosis considering FDA-approved Forteo, Tymlos, or Evenity with endocrinology or rheumatology.
- • Adult exploring off-label use of FDA-approved peptide with documented risk-benefit assessment and informed consent per AMA Code of Medical Ethics.
- • Adult considering compounded peptide product with verified 503A or 503B pharmacy accreditation and third-party testing.
- • Adult considering research-grade peptide outside FDA framework being redirected to clinical trial enrollment or validated alternatives.
- • Patient with complex comorbidities or multi-system disease requiring multi-specialty coordination across primary care, endocrinology, rheumatology, cardiology.
- • Patient with specific contraindications to FDA-approved peptide requiring alternative validated therapy within evidence-graded scope.
- • Patient pursuing telehealth peptide consultation with established physician-patient relationship per state regulations and licensed practitioner.
Verdict
Physicians follow evidence-graded frameworks when recommending peptide therapy. The decision spans five stages. Stage one is comprehensive evaluation including history, exam, and indicated labs. Stage two matches patient presentation to FDA-approved indications when available. Stage three assesses risk-benefit for off-label or compounded options. Stage four establishes documented informed consent per AMA Code of Medical Ethics. Stage five establishes monitoring plan with appropriate follow-up cadence. FDA-approved peptides have the strongest evidence and regulatory foundation. Wegovy and Ozempic hold FDA approval for chronic weight management and type 2 diabetes. Zepbound and Mounjaro hold FDA approval for chronic weight management and type 2 diabetes. Forteo holds FDA approval for postmenopausal, male, and glucocorticoid-induced osteoporosis. Tymlos holds FDA approval for postmenopausal and male osteoporosis at high fracture risk. Evenity holds FDA approval for postmenopausal osteoporosis at high fracture risk. Off-label use of FDA-approved peptides is legal under AMA Code of Medical Ethics. The framework requires documented informed consent and risk-benefit assessment. Compounded peptides come from 503A or 503B pharmacies under state or FDA oversight. Physician due diligence on pharmacy quality assurance is essential. Research-grade peptides without FDA approval are generally outside validated practice. Patient self-sourcing from research suppliers incurs unknown safety risks. Specialty coordination strengthens complex decisions across primary care, endocrinology, weight medicine, rheumatology, and other fields. PSI maintains a vetted directory of practitioners with peptide experience for patients pursuing evidence-graded peptide therapy. Anyone framing research-grade peptides as substitute for validated FDA-approved therapy is reading further than the evidence supports.
In Plain Terms
Peptide therapy ranges from FDA-approved drugs to compounded products to research-grade compounds. FDA-approved peptides have the strongest evidence and clearest prescribing path. Examples include Wegovy and Ozempic for weight management and diabetes. Other FDA-approved peptides include Forteo, Tymlos, and Evenity for osteoporosis. Off-label use of FDA-approved peptides is legal with informed consent. Compounded peptides come from licensed pharmacies but lack FDA pre-market approval. Quality varies by compounding pharmacy practices and third-party testing. Research-grade peptides from online suppliers are outside validated medical practice. Most physicians follow a structured framework when recommending peptides. The framework includes evaluation, evidence review, informed consent, and monitoring. Primary care prescribes common FDA-approved peptides. Specialists handle complex cases. See primary care, endocrinology, or weight medicine for evaluation.
Peptides are short chains of amino acids that act like signaling messengers in the body. Some peptides are FDA-approved drugs you can get from any doctor with a prescription. Wegovy and Ozempic are FDA-approved for weight loss and diabetes. Forteo and Tymlos are FDA-approved for osteoporosis. Other peptides are compounded by special pharmacies and require more careful evaluation. Some peptides sold online are not approved for human use and should be avoided. Most doctors follow a clear framework when deciding whether to recommend a peptide. They evaluate your health, look at the evidence, discuss options with you, and create a monitoring plan.
Patients exploring peptide therapy typically work with primary care, endocrinology, weight medicine, rheumatology, or other relevant specialty practitioners who navigate the FDA-approved, off-label, and compounded peptide framework per AMA Code of Medical Ethics. PSI maintains a vetted directory of practitioners with peptide experience.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Contexts
- • Adult with FDA-approved-indication condition (direct prescribing per FDA prescribing information)
- • Adult with chronic weight management need (Wegovy / Zepbound / Saxenda primary care or weight medicine)
- • Adult with type 2 diabetes and CV risk (Ozempic / Mounjaro / Victoza endocrinology or primary care)
- • Adult with high fracture risk osteoporosis (Forteo / Tymlos / Evenity endocrinology or rheumatology)
- • Adult exploring off-label use (documented risk-benefit and informed consent per AMA Code)
- • Adult considering compounded peptide (503A or 503B pharmacy quality assurance verification)
- • Adult considering research-grade peptide (refer to clinical trial enrollment rather than self-sourcing)
- • Patient with complex comorbidities (multi-specialty coordination across primary care and specialty)
- • Patient with specific contraindications (alternative validated therapy within evidence-graded scope)
- • Patient on telehealth (established physician-patient relationship per state regulations)
Important Context
Your physician will weigh your specific clinical context, evaluation results, medical history, comorbidities, medications, and preferences when making any prescribing decision. The framework described here is general and does not substitute for individualized clinical judgment.
Educational content only. Discuss with your physician before starting, stopping, or modifying any therapy. Self-sourcing peptides outside validated clinical practice incurs unknown safety risks.
Sources and Citations
- [1] FDA Prescribing Information: Wegovy (semaglutide) injection 2.4 mg · 2024 · FDA NDA 215256 · Source
- [2] FDA Prescribing Information: Ozempic (semaglutide) injection · 2024 · FDA NDA 209637 · Source
- [3] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
- [4] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with boxed warning · 2019 · FDA NDA 761062 · Source
- [5] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
- [6] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
- [7] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/MS/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol · Circulation · 2018 · DOI
- [8] Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update · Endocrine Practice · 2020 · DOI
- [9] Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline · Journal of Clinical Endocrinology and Metabolism · 2019 · DOI
- [10] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
- [11] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
- [12] FDA Compounding Quality Act framework: 503A pharmacy compounding under state oversight; 503B outsourcing facilities under FDA registration · US Food and Drug Administration · 2023 · Source
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.